A 2026 cross-sectional study of 369 people with multiple sclerosis in Libya found that vitamin D levels showed no clinically meaningful connection to disability or disease flare-up rates. According to Gram Research analysis, differences in vitamin D were too small to matter for patient outcomes, though the study doesn’t rule out vitamin D’s potential role in early disease or inflammation.
A new study of 369 people with multiple sclerosis in Libya found that vitamin D levels weren’t strongly connected to how disabled people became or how often they had disease flare-ups. While vitamin D is often discussed as important for MS, this research suggests it may not directly affect the disability people experience from the disease. The findings don’t rule out that vitamin D might help with inflammation or early disease stages, but they suggest we need longer studies to understand vitamin D’s real role in MS.
Key Statistics
A 2026 cross-sectional study of 369 Libyan adults with multiple sclerosis found that vitamin D levels showed no clinically meaningful association with disability scores, with effect estimates falling within the prespecified equivalence margin of ±0.30 EDSS points.
In the same 2026 study of 369 MS patients, vitamin D levels were similarly unrelated to disease relapse rates, with results within the equivalence margin of ±0.25 annualized relapse rate units.
A 2026 analysis of 369 people with MS found that an exploratory threshold analysis suggested a small increase in odds of higher disability at vitamin D levels below 20 ng/mL (OR 1.47), but this finding was not supported by continuous analyses and should be interpreted cautiously.
The Quick Take
- What they studied: Whether vitamin D levels in the blood are connected to how much disability people with MS experience and how often they have disease flare-ups
- Who participated: 369 adults with multiple sclerosis from medical centers in Libya, representing a population group that hasn’t been studied much in vitamin D research
- Key finding: Vitamin D levels showed no meaningful connection to disability levels or relapse rates. The study found the effects were too small to matter clinically, even when researchers looked at different vitamin D ranges.
- What it means for you: If you have MS, don’t assume that raising your vitamin D levels will significantly reduce your disability or prevent flare-ups based on this evidence. However, vitamin D may still be important for overall health and other aspects of MS—talk to your doctor about your individual situation.
The Research Details
Researchers collected blood samples and health information from 369 people with MS at the same point in time (a cross-sectional design). They measured vitamin D levels in everyone’s blood and compared these levels to how disabled each person was using a standard disability scale called the EDSS, and how often people had disease flare-ups. The researchers adjusted their analysis to account for other factors that might affect disability, like age, gender, lifestyle habits, and MS medications.
They used a special statistical approach called equivalence testing, which asks whether vitamin D differences are small enough to be clinically unimportant—not just whether they’re statistically significant. They also looked at whether the relationship might be different at certain vitamin D thresholds, and tested whether measurement errors in vitamin D testing changed their conclusions.
This approach matters because it directly answers whether vitamin D changes would meaningfully improve MS outcomes. Many previous studies only asked if vitamin D was statistically different between groups, without considering whether those differences actually matter for patients. By studying an underrepresented population (Libyan adults), the research also helps fill a gap in MS research that has historically focused on European and North American populations.
This study’s strengths include a reasonable sample size of 369 people, careful adjustment for multiple factors that could affect results, and use of equivalence testing to determine clinical meaningfulness. Limitations include its cross-sectional design, which captures only one moment in time and cannot prove cause-and-effect relationships. The study also cannot determine whether vitamin D might affect MS progression over months or years, only current disability levels.
What the Results Show
When researchers looked at the relationship between vitamin D levels and disability using the EDSS scale, they found very small effects that fell within their predetermined range of ‘clinically unimportant’ differences. This means that even though vitamin D and disability might be mathematically related, the relationship is too weak to matter for patient care. Similarly, vitamin D levels showed no meaningful connection to how often people experienced disease flare-ups (relapses).
The researchers also looked at whether vitamin D might have a stronger effect at certain thresholds—for example, whether very low vitamin D might be particularly harmful. They found a small increase in odds of higher disability at one threshold, but this finding wasn’t supported when they looked at the full range of vitamin D levels, suggesting it may have been a chance finding.
When the researchers tested whether measurement errors in vitamin D testing might have hidden a real effect, the results remained unchanged. They also looked for non-linear relationships (where vitamin D might matter more at certain levels), but found little evidence of this. These consistency checks strengthen confidence that vitamin D levels truly don’t have a strong clinical connection to current disability in this population.
Previous research on vitamin D and MS has produced mixed results, with some studies suggesting vitamin D is important and others finding weaker connections. According to Gram Research analysis, this study adds important evidence that vitamin D’s role in MS may be more complex than initially thought. Rather than directly affecting established disability, vitamin D might influence earlier disease processes or inflammatory markers that weren’t measured in this study. The findings align with growing recognition that vitamin D’s importance in MS may depend on when it’s measured (early vs. late disease) and what outcomes we’re looking at.
The biggest limitation is that this study captured only one moment in time. It cannot show whether vitamin D changes over months or years affect disability development. The study also cannot prove that vitamin D doesn’t matter—only that it doesn’t have a strong connection to current disability levels. Additionally, the study was conducted in Libya, so results may not apply equally to people with MS in other parts of the world with different genetics, sun exposure, and healthcare practices. The study also couldn’t measure some factors that might matter, like sun exposure or dietary vitamin D intake.
The Bottom Line
Based on this evidence, don’t rely on vitamin D supplementation as a primary strategy to reduce MS disability or prevent flare-ups. However, maintaining adequate vitamin D levels remains important for bone health and overall wellness—discuss appropriate vitamin D levels with your neurologist. If you have MS, focus on disease-modifying medications prescribed by your doctor, which have stronger evidence for reducing disability. Vitamin D may still play a role in early disease or inflammation that this study couldn’t measure, so don’t dismiss it entirely, but manage expectations about its direct impact on disability.
People with MS should care about these findings because they clarify realistic expectations for vitamin D supplementation. Healthcare providers treating MS should use this evidence to avoid over-emphasizing vitamin D as a disability treatment. Researchers should care because this study highlights the need for longer-term studies that track vitamin D and disability over time. People in other populations (not just Libyan) should note that these findings may or may not apply to them.
If you’re considering vitamin D supplementation for MS, don’t expect to see changes in disability or relapse rates over weeks or months based on this evidence. Any benefits from vitamin D for MS would likely take months to years to appear, if they exist at all. This study suggests that if vitamin D does help MS, it probably works through mechanisms other than directly reducing established disability.
Frequently Asked Questions
Does vitamin D help reduce disability in multiple sclerosis?
A 2026 study of 369 MS patients found no clinically meaningful connection between vitamin D levels and disability. While vitamin D remains important for bone health, this research suggests it doesn’t directly reduce MS-related disability based on current evidence.
Should I take vitamin D supplements if I have MS?
Discuss vitamin D supplementation with your neurologist based on your individual vitamin D levels and bone health needs, not as a primary MS disability treatment. This 2026 study suggests vitamin D supplementation won’t significantly reduce your disability or prevent flare-ups.
Can low vitamin D make MS worse?
A 2026 cross-sectional study of 369 MS patients found no strong evidence that low vitamin D directly worsens established disability. However, the study couldn’t measure whether vitamin D affects early disease processes or inflammation, so vitamin D may still matter in ways this research couldn’t detect.
What’s more important for MS: vitamin D or disease-modifying drugs?
Disease-modifying medications have much stronger evidence for reducing MS disability and relapses. While vitamin D supports overall health, this 2026 study of 369 patients found it doesn’t directly affect disability, so prioritize your prescribed MS medications.
How long does it take to see benefits from vitamin D in MS?
This cross-sectional study captured only one moment in time, so it cannot determine timelines. However, the weak connection between vitamin D and disability suggests benefits, if any exist, would likely take months to years to appear.
Want to Apply This Research?
- Track your vitamin D levels quarterly (every 3 months) through blood tests, and separately track your MS disability symptoms using the same scale your neurologist uses. This allows you to see whether changes in vitamin D correlate with your personal disability patterns, even though population-level data suggests weak connections.
- Rather than focusing on vitamin D supplementation as an MS treatment, use the app to ensure you’re taking your prescribed disease-modifying therapy consistently and tracking adherence. Log vitamin D supplementation if you take it for bone health, but monitor your actual MS outcomes (relapses, disability) as the primary measure of disease control.
- Set up long-term tracking of vitamin D levels and disability scores over 6-12 months to identify your personal patterns. While this study found weak population-level connections, individual responses vary. Share these tracked trends with your neurologist to make personalized decisions about vitamin D supplementation.
This research summary is for educational purposes and should not replace professional medical advice. The findings suggest vitamin D doesn’t have a strong direct effect on MS disability, but this doesn’t mean vitamin D is unimportant for your overall health. Always consult your neurologist or healthcare provider before making changes to vitamin D supplementation or MS treatment. This study was conducted in Libya and may not apply equally to all populations. Individual responses to vitamin D vary, and your doctor can help determine appropriate vitamin D levels for your specific situation.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.